Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 14, 2026Blood Cancer Discovery

Ibrutinib with venetoclax in patients with relapsed/refractory chronic lymphocytic leukemia: A phase II study

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMahesh SwaminathanThe University of Texas MD Anderson Cancer CenterAFAlessandra FerrajoliMemorial Sloan Kettering Cancer CenterPTPhilip A. Thompson

Discussion

Loading...

Member takes

Implication

Phase II study shows improved outcomes in relapsed/refractory CLL patients with combined treatment, suggesting effective therapy options.

Key Points

  • The study aims to assess the efficacy of ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) patients.
  • Enrolled 80 patients with R/R CLL from July 2016 to September 2018
  • Administered ibrutinib for the first 3 cycles, followed by ibrutinib plus venetoclax for 24 cycles
  • Monitored responses including complete response (CR) and measurable residual disease (MRD) rates
  • 67% of patients achieved complete response (CR) or CR with incomplete recovery (CRi)
  • 61% of patients had undetectable measurable residual disease (MRD) at bone marrow
  • Estimated 7-year progression-free survival (PFS) rate was 63.3%
  • 38% of patients experienced grade ≥3 neutropenia, and 13% experienced thrombocytopenia

Cite This Study

Swaminathan et al. (2026) studied this question.

synapsesocial.com/papers/699011032ccff479cfe5762bhttps://doi.org/10.1158/2643-3230.bcd-25-0345
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.2024 · 16 citations
  2. 2Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study2024 · 9 citations
  3. 3Optimal three-stage designs for phase II cancer clinical trials1997 · 140 citations
  4. 4Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status2022 · 15 citations
  5. 5Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial2025 · 10 citations